<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Terapevticheskii arkhiv</journal-id><journal-title-group><journal-title xml:lang="en">Terapevticheskii arkhiv</journal-title><trans-title-group xml:lang="ru"><trans-title>Терапевтический архив</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0040-3660</issn><issn publication-format="electronic">2309-5342</issn><publisher><publisher-name xml:lang="en">LLC Obyedinennaya Redaktsiya</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">30754</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Editorial article</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Передовая статья</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Study of bone marrow microvessel density is one of the diagnostic approaches in patients with Ph-negative chronic myeloproliferative diseases</article-title><trans-title-group xml:lang="ru"><trans-title>ИССЛЕДОВАНИЕ ПЛОТНОСТИ МИКРОСОСУДОВ КОСТНОГО МОЗГА - ОДИН ИЗ ДИАГНОСТИЧЕСКИХ ПОДХОДОВ У БОЛЬНЫХ Ph-НЕГАТИВНЫМИ ХРОНИЧЕСКИМИ МИЕЛОПРОЛИФЕРАТИВНЫМИ ЗАБОЛЕВАНИЯМИ</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Sokolova</surname><given-names>Manana Aleksandrovna</given-names></name><name xml:lang="ru"><surname>Соколова</surname><given-names>Манана Александровна</given-names></name></name-alternatives><bio xml:lang="ru"><p>канд. мед. наук, ст. науч. сотр., отд-ние химиотерапии лейкозов и патологии эритрона; ГУ Гематологический научный центр РАМН</p></bio><email>s_manana@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Khoroshko</surname><given-names>Nina Dmitrievna</given-names></name><name xml:lang="ru"><surname>Хорошко</surname><given-names>Нина Дмитриевна</given-names></name></name-alternatives><bio xml:lang="ru"><p>проф., рук. отд-ния химиотерапии лейкозов и патологии эритрона; ГУ Гематологический научный центр РАМН</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Tsvetaeva</surname><given-names>Nina Valentinovna</given-names></name><name xml:lang="ru"><surname>Цветаева</surname><given-names>Нина Валентиновна</given-names></name></name-alternatives><bio xml:lang="ru"><p>канд. мед. наук, вед. науч. сотр., отд-ние ХТЛ; ГУ Гематологический научный центр РАМН</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Semenova</surname><given-names>Elena Aleksandrovna</given-names></name><name xml:lang="ru"><surname>Семенова</surname><given-names>Елена Александровна</given-names></name></name-alternatives><bio xml:lang="ru"><p>канд. мед. наук, вед. науч. сотр., патолого-анатомическое отд-ние; ГУ Гематологический научный центр РАМН</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kaplanskaya</surname><given-names>Irina Borisovna</given-names></name><name xml:lang="ru"><surname>Капланская</surname><given-names>Ирина Борисовна</given-names></name></name-alternatives><bio xml:lang="ru"><p>канд. мед. наук, вед. науч. сотр., патолого-анатомическое отд-ние; ГУ Гематологический научный центр РАМН</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Frank</surname><given-names>Georgiy Avraamovich</given-names></name><name xml:lang="ru"><surname>Франк</surname><given-names>Георгий Авраамович</given-names></name></name-alternatives><bio xml:lang="ru"><p>проф., рук. патолого-анатомического отд-ния; ГУ Гематологический научный центр РАМН</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Misyurin</surname><given-names>Andrey Vital'evich</given-names></name><name xml:lang="ru"><surname>Мисюрин</surname><given-names>Андрей Витальевич</given-names></name></name-alternatives><bio xml:lang="ru"><p>канд. мед. наук, рук. отд-ния генной инженерии; ГУ Гематологический научный центр РАМН</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Sokolova</surname><given-names>M A</given-names></name><bio xml:lang="en"><p>Hematology Research Center, Russian Academy of Medical Sciences</p></bio><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name><surname>Khoroshko</surname><given-names>N D</given-names></name><bio xml:lang="en"><p>Hematology Research Center, Russian Academy of Medical Sciences</p></bio><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name><surname>Tsvetayeva</surname><given-names>N V</given-names></name><bio xml:lang="en"><p>Hematology Research Center, Russian Academy of Medical Sciences</p></bio><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name><surname>Semenova</surname><given-names>E A</given-names></name><bio xml:lang="en"><p>Hematology Research Center, Russian Academy of Medical Sciences</p></bio><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name><surname>Kaplanskaya</surname><given-names>I B</given-names></name><bio xml:lang="en"><p>Hematology Research Center, Russian Academy of Medical Sciences</p></bio><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name><surname>Frank</surname><given-names>G A</given-names></name><bio xml:lang="en"><p>Hematology Research Center, Russian Academy of Medical Sciences</p></bio><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name><surname>Misyurin</surname><given-names>A V</given-names></name><bio xml:lang="en"><p>Hematology Research Center, Russian Academy of Medical Sciences</p></bio><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en"></institution></aff><aff><institution xml:lang="ru">ГУ Гематологический научный центр РАМН</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Hematology Research Center, Russian Academy of Medical Sciences</institution></aff><aff><institution xml:lang="ru"></institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2010-12-15" publication-format="electronic"><day>15</day><month>12</month><year>2010</year></pub-date><volume>82</volume><issue>12</issue><issue-title xml:lang="en">NO12 (2010)</issue-title><issue-title xml:lang="ru">ТОМ 82, №12 (2010)</issue-title><fpage>47</fpage><lpage>51</lpage><history><date date-type="received" iso-8601-date="2020-04-09"><day>09</day><month>04</month><year>2020</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2010, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2010, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2010</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://ter-arkhiv.ru/0040-3660/article/view/30754">https://ter-arkhiv.ru/0040-3660/article/view/30754</self-uri><abstract xml:lang="en"><p>Aim. To define an association of bone marrow microvessel density (MVD) with histological properties (the magnitude of fibrosis and quantification of megakaryocytes (MGKC)) in patients with Ph-negative chronic myeloproliferative diseases (CMPD).
Subjects and methods. MVD was analyzed in 93 patients with different forms of CMPD, by estimating histological parameters. True polycythemia (TP) was present in 28 patients; 20 patients had essential thrombocythemia (ET), 36 had subleukemic myelosis, out them 6 were in a prefibrotic stage, and 9 with diagnosed post-TP(ET) myelofibrosis. The grade of myelofibrosis was estimated from the degree of bone marrow fibrosis as 0, 1, 2, and 3 and the clusters of MGKC were in accordance with degrees: 0, 1, and 2. MVD was studied from the absolute number of CD34-positive vascular structures.
Results. In patients with TP, fibrosis was defined as grade 0 and 1 in 23 (82%) and 5 (18%) cases, respectively. The content of reticulin fiber was in the normal range in 19 (95%) of the 20 patients with ET. The clusters of MGKC of grades 1 and 2 showed an even distribution among patients with ET and those with TP. Fibrosis was absent in all the patients (n = 6) with prefibrotic-stage primary myelofibrosis (PMF). The patients with PMF had high MVD values [6.5 (range 2.8-22)] than those with TP [4.0 (range 1.76-10.2)] or ET [3.7 (range 2-8.5)] and the controls [3.2 (range 2-4.1)] (p &lt; 0.001) confirming that angiogenesis is uninvolved at the onset of disease in patients with ET and those with TP. The patients with prefibrotic-stage PMF had higher values [6.0 (range 4.8-10.6)] than those with ET [3.7 (range 2-8.5)] (p &lt; 0.001). This suggests that angiogenesis is an early sign preceding the development of fibrosis.
Conclusion. Bone marrow angiogenesis assessment (from MVD measurements) may be an additional criterion for the diagnosis of disease evolution and an additional criterion between ET and PMF in a prefibrotic stage.</p></abstract><trans-abstract xml:lang="ru"><p>Цель исследования. Определить взаимосвязь плотности микрососудов (ПМС) в костном мозге с гистологическими свойствами (выраженность фиброза и количественная оценка мегакариоцитов) у больных Ph-негативными хроническими миелопролиферативными заболеваниями (ХМПЗ).
Материалы и методы. Проведен анализ ПМС у 93 больных с различными формами ХМПЗ с оценкой гистологических параметров. Истинная полицитемия (ИП) была у 28 больных, у 20 больных - эссенциальная тромбоцитемия (ЭТ), у 36 - сублейкемический миелоз, из них 6 в стадии префиброза и 9 с диагностированным пост-ИП(ЭТ) миелофиброзом. Степень миелофиброза оценивали по степеням фиброза костного мозга 0, 1, 2, 3 и кластеры мегакариоцитов (МГКЦ) в соответствии со степенями: 0, 1, 2. Плотность микрососудов исследовали по абсолютному числу положительных по CD34 сосудистых структур.
Результаты. Степень фиброза у пациентов с ИП была 0-й в 23 (82%) случаях и 1-й степени в 5 (18%). Из 20 больных с ЭТ содержание ретикулинового волокна было в пределах нормы у 19 (95%). Кластеры МГКЦ 1-й, 2-й степени распределялись равномерно между больными с ЭТ и ИП. У всех пациентов с ПМФ в префиброзной стадии (6 больных) фиброз отсутствовал. У пациентов с ПМФ были выше ПМС - 6,5 (2,8-22), чем у больных с ИП - 4,0 (1,76-10,2), с ЭТ - 3,7 (2-8,5) и в контроле - 3,2 (2-4,1) (p &lt; 0,001), подтверждая, что ангиогенез не вовлечен в дебюте заболевания у больных ЭТ и ИП. У пациентов с ПМФ в префиброзной стадии имелись более высокие ПМС 6,0 (4,8-10,6), чем у пациентов с ЭТ - 3,7 (2-8,5) (p &lt; 0,001). Это позволяет предположить, что ангиогенез - раннее явление, предшествующее развитию фиброза.
Заключение. Оценка ангиогенеза костного мозга (по данным измерения ПМС) может быть дополнительным критерием для диагностики эволюции болезни и являться дополнительным диагностическим критерием между ЭТ и ПМФ на префиброзной стадии.</p></trans-abstract><kwd-group xml:lang="en"><kwd>chronic myeloproliferative diseases</kwd><kwd>microvessel density</kwd><kwd>bone marrow</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>хронические миелопролиферативные заболевания</kwd><kwd>плотность микрососудов</kwd><kwd>костный мозг</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Mesa R. A., Hanson C. A., Rajkumar S. V. et al. Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia. Blood 2000; 96: 3374-3380.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Ponzoni M., Savage D. G., Ferreri A. J. et al. Chronic idiopathic myelofibrosis: independent prognostic importance of bone marrow microvascular density evaluated by CD105 (endoglin) immunostaining. Modern Pathol. 2004; 17: 1513-1520.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Mesa R. A., Steensma D. P., Pardanini A. et al. A phase 2 trial of combination low-dose thalidomide and prednisolone for the treatment of myelofibrosis with myeloid metaplasia. Blood 2003; 101: 2534-2541.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Elliot M. A., Mesa R. A., Li C. Y. et al. Thalidomide treatment in myelofibrosis with myeloid metaplasia. Br. J. Haematol. 2002; 117: 288-296.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Tefferi A., Cortes J., Verstovsek S. et al. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood 2006; 108: 1158-1164.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Arora B., Ho C. L., Hoyer I. D. et al. Bone marrow angiogenesis and its clinical correlates in myelofibrosis with myeloid metaplasia. Haematologica 2004; 89: 1454-1458.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Panteli K., Zagorianakou N., Agnantis N. J. et al. Clinical correlation of bone marrow microvessel density in essential thrombocytemia. Acta Haematol. 2005; 114: 99-103.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Weidner N. Tumor angiogenesis: review of current applications in tumor prognostication. Semin. Diagn. Pathol. 1993; 10: 302-313.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Aguayo A., Kantarjian H., Manshouri T. et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 2000; 96: 2240-2245.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Keith T., Araki Y., Ohyagi M. et al. Regulation of angiogenesis in the bone marrow of myelodysplastic syndromes transforming to overt leukemia. Br. J. Haematol. 2007; 137: 206-215.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Marchetti M., Barosi G., Balestri F. et al. Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase 2 trial. J. Clin. Oncol. 2004; 22: 424-431.</mixed-citation></ref></ref-list></back></article>
